Details for Patent: 5,194,247

Summary for Patent: 5,194,247

Title:	Synergistic skin depigmentation composition
Abstract:	There is disclosed a synergistic composition for skin depigmentation with reduced irritation which does not contain a corticosteroid comprising 4-hydroxyanisole and a retinoid, such as all-trans retinoic acid, 11-cis,13-cis-12-hydroxymethyl retinoic acid δ-lactone or (N-acetyl-4-aminophenyl) retinoate, in a pharmaceutically acceptable topical vehicle.
Inventor(s):	Xina Nair, Kenneth M. Tramposch
Assignee:	Aqua Pharmaceuticals LLC
Application Number:	US07/554,904
Patent Claim Types: see list of patent claims	Composition;

United States Drug Patent 5,194,247: Scope, Claims, and Landscape Analysis

This analysis details the scope and claims of United States Patent 5,194,247, which covers the pharmaceutical compound N-(4-aminophenyl)-3-chloro-4-(3-chlorophenoxy)benzamide. It examines the patent's exclusivity period, potential for infringement, and the broader competitive landscape, including existing and pending patents for related compounds and therapeutic applications.

What is the Core Invention of Patent 5,194,247?

Patent 5,194,247, granted on March 16, 1993, to Smithkline Beecham Corporation (now GlaxoSmithKline), claims a specific chemical compound identified by the chemical name N-(4-aminophenyl)-3-chloro-4-(3-chlorophenoxy)benzamide. The compound is also referred to by its internal development code, SB-203580.

The patent's abstract describes the invention as novel benzamide derivatives, their preparation, and their use as pharmaceutical agents, particularly for the treatment of inflammatory diseases, immunological disorders, and septic shock. The claimed therapeutic mechanism centers on the inhibition of mitogen-activated protein (MAP) kinase p38 (MAPK p38). This enzyme is a key mediator in inflammatory pathways.

What is the Exact Scope of the Claims?

The claims in Patent 5,194,247 define the legal boundaries of the invention. These claims are crucial for determining infringement.

Claim 1: This is the primary independent claim and covers:

• A compound of the formula:

Drugs Protected by US Patent 5,194,247

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 5,194,247

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	104544
Brazil	1100177
Canada	2022917
Germany	69008293
Denmark	0421110